Full-Time

Regional Business Director

Oncology

Updated on 11/14/2024

Corcept Therapeutics

Corcept Therapeutics

201-500 employees

Develops cortisol modulators for medical conditions

Biotechnology
Healthcare

Compensation Overview

$235k - $274kAnnually

Expert

Remote in USA

Category
Strategic Account Management
Sales & Account Management
Required Skills
Branding/Brand Strategy
Requirements
  • Proven experience in successfully launching key products/brands in the oncology field
  • Has a track record in launching and managing sales of oncology products, particularly in the GYN/ONC therapeutic area
  • Previous success building and leading high-performing teams
  • Inspirational leadership style with the ability to motivate and encourage accountability
  • Strategic thinker with strong business acumen and the ability to translate strategy into actionable sales plans
  • Bachelor’s degree plus 10+ years of commercial experience in pharmaceuticals
  • Extensive understanding and experience in both clinical aspects and the business of oncology, with a focus on gyne/onc
  • In-depth knowledge of U.S. payer and market access dynamics
Responsibilities
  • Cultivate a ‘high trust’ culture that inspires excellence, puts people first, and works together to bring out the best in individuals with an unwavering commitment to patients
  • Collaborate with cross-functional leaders and teams to develop comprehensive brand and sales strategies. Lead the execution of these strategies to drive revenue growth and market share within their Region
  • Work with Vice President, Oncology, Human Resources and Talent Acquisition to lead the recruitment, development, and retention of top-tier talent
  • Execute the launch plans to ensure a successful market introduction and rapid adoption of new products
  • Establish sales goals and monitor performance against targets
  • Identify and prioritize key accounts, including oncologists, hospitals, and cancer treatment centers
  • Build and maintain strong relationships with key opinion leaders (KOLs), healthcare professionals, and other stakeholders in the GYN/ONC therapeutic area
  • Conduct market analysis to understand regional trends, competitive landscape, and customer needs
  • Collaborate with marketing, medical affairs, and other cross-functional teams to align strategies and ensure consistent messaging

Corcept Therapeutics focuses on developing treatments that regulate cortisol, a hormone important for stress response, metabolism, and immune function. Their main product, Korlym, is the first FDA-approved treatment for Cushing's syndrome, a condition caused by excessive cortisol. The company has discovered over 1,000 selective cortisol modulators and aims to expand its offerings with new treatments in development. Unlike many competitors, Corcept emphasizes both research and patient education, providing resources to improve understanding and care for cortisol-related conditions. The goal of Corcept is to advance the treatment of serious medical conditions linked to cortisol imbalance.

Company Stage

IPO

Total Funding

$42.6M

Headquarters

Menlo Park, California

Founded

1998

Growth & Insights
Headcount

6 month growth

23%

1 year growth

31%

2 year growth

53%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from firms like Intrinsic Edge Capital and Jackson Creek Investment Advisors indicate strong market confidence in Corcept's growth potential.
  • The appointment of experienced leaders like Roberto Vieira and Monica Tellado suggests a strategic focus on expanding into oncology and emerging markets.
  • Corcept's commitment to patient and medical education enhances its reputation and fosters better patient outcomes.

What critics are saying

  • Ongoing legal disputes, such as the antitrust lawsuit from Teva, could result in financial and operational setbacks.
  • The loss of the Korlym patent lawsuit to Teva poses a significant threat to Corcept's revenue stream from its flagship product.

What makes Corcept Therapeutics unique

  • Corcept Therapeutics specializes exclusively in cortisol modulation, setting it apart from broader-focused biopharmaceutical companies.
  • Their flagship product, Korlym, is the first FDA-approved treatment for hypercortisolism in Cushing's syndrome, giving them a unique market position.
  • Corcept's extensive R&D pipeline with over 1,000 discovered selective cortisol modulators highlights their commitment to innovation in this niche field.

Help us improve and share your feedback! Did you find this helpful?